Log In Get Started
Press Releases September 1, 2026 07:00 AM

Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Tenax Therapeutics to Present at 2026 Cantor Global Healthcare Conference

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
TENX

Tenax Therapeutics, a clinical-stage pharmaceutical company focusing on cardiopulmonary therapies, announced that CEO Chris Giordano will present at the upcoming 2026 Cantor Global Healthcare Conference. The company is developing levosimendan for treating pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF), a condition with no approved therapies to date.

Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
TENX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Tenax Therapeutics is developing levosimendan, a novel therapy targeting PH-HFpEF, a widespread form of pulmonary hypertension without any currently approved treatment.
  • The company is currently in Phase 3 development, indicating advanced clinical trials towards potential regulatory approval.
  • Participation in the Cantor Global Healthcare Conference provides an opportunity to communicate progress to investors and analysts, potentially attracting more investor interest.

CHAPEL HILL, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) announced today that Chris Giordano, President & Chief Executive Officer, will present at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 a.m. ET.

The live and archived webcast of the presentation will be accessible from the Company’s investor relations webpage.

About Tenax Therapeutics
Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit www.tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.

Contact:
Investor and Media:
Argot Partners
tenax@argotpartners.com 


Risks

  • Development-stage company risk with levosimendan still in clinical trials and no guarantee of successful regulatory approval, impacting future revenue potential.
  • Market uncertainty due to the absence of approved treatments in the PH-HFpEF space which could complicate commercialization and adoption if approved.
  • Potential volatility in stock price around investor presentations and trial results, reflecting sensitivity to clinical and regulatory developments.

More from Press Releases

Lorenzo Grandi, STMicroelectronics’ President and CFO to speak at Citi investor conference Sep 2, 2026 Skyworks Announces Extension of Expiration Date of Exchange Offers for Qorvo’s Senior Notes due 2029 and 2031 Sep 1, 2026 Quantumsphere Acquisition Corporation Announces Termination of the Agreement and Plan of Merger with SACH Pte. Ltd. Sep 1, 2026 Enovix’s TAA-Compliant Battery Manufacturing Strengthens Position with U.S. Defense Supply Chain Sep 1, 2026 Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange Sep 1, 2026